The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to ...

Swiss generic and biosimilar medicines company Sandoz (SWX: SDZ) today announced that Wyost (denosumab) and Jubbonti ...

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

The global biosimilars market growth is driven by increasing number of biosimilar approvals and rising number of biologics going off-patent.A biosimilar is a biological product that is similar to a ...

Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance ...